IONSYS Drug Patent Profile

Which patents cover Ionsys, and what generic alternatives are available?

Ionsys is a drug marketed by The Medicines Co and is included in one NDA. There are seven patents protecting this drug.

This drug has eighty-six patent family members in eighteen countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this compound. Additional details are available on the fentanyl hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Ionsys

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 30, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for IONSYS

International Patents:	86
US Patents:	7
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	14
Clinical Trials:	7
Patent Applications:	118
DailyMed Link:	IONSYS at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for IONSYS

Constraining patent/regulatory exclusivity:

9,364,656

NDA:

021338

Dosage:

SYSTEM;IONTOPHORESIS, TRANSDERMAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for IONSYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The Medicines Company	Phase 4
Hospital for Special Surgery, New York	Phase 4
Incline Therapeutics, Inc.	Phase 3

See all IONSYS clinical trials

US Patents and Regulatory Information for IONSYS

IONSYS is protected by seven US patents.

This potential generic entry date is based on patent 9,364,656.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,428,709		Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	9,095,706		Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	9,364,656
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,428,708
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,781,571		Y
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006		DISCN	Yes	No	8,301,238		Y

Expired US Patents for IONSYS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	7,302,293
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	6,181,963
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	7,018,370
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	6,842,640
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	5,232,438
The Medicines Co	IONSYS	fentanyl hydrochloride	SYSTEM;IONTOPHORESIS, TRANSDERMAL	021338-001	May 22, 2006	6,195,582

International Patents for IONSYS

When does loss-of-exclusivity occur for IONSYS?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Hong Kong

India

Israel

Japan

Mexico

New Zealand

Portugal

Russian Federation

Singapore

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering IONSYS around the world.

Country	Patent Number	Title	Estimated Expiration
China	1147330
United Kingdom	2317115	Device for transdermal electrotransport delivery of fentanyl and sufentanil
Portugal	2858715
European Patent Office	2691148	DISPOSITIF DE TRANSPORT D'ÉLECTRONS CONSTITUÉ DE DEUX PARTIES (TWO-PART ELECTROTRANSPORT DEVICE)
South Korea	20170016890	스위치 검증 회로 및 방법 (SWITCH VALIDATION CIRCUIT AND METHOD)
Japan	H11506684

Supplementary Protection Certificates for IONSYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1635783	122014000024	Germany		PRODUCT NAME: FENTANYL IN ALLEN DEM SCHUTZ DES GRUNDPATENTS UNTERLIEGENDEN FORMEN; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100831
0383579	C960030	Netherlands		PRODUCT NAME: REMIFENTANYLUM, DESGEWENST IN DE VORM VAN EEN ZUURADDITIE-ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 20601 - RVG 20603 19961015; 36335.00.00, 36335.01.00, 36335.02.00 19960517
0836511	SPC/GB06/022	United Kingdom		PRODUCT NAME: FENTANYL HYDROCHLORIDE; REGISTERED: UK EU/1/05/326/001 20060124
0901368	C300523	Netherlands		PRODUCT NAME: FENTANYL; REGISTRATION NO/DATE: EU/2/11/127/001 20111006
1635783	CA 2014 00016	Denmark		PRODUCT NAME: FENTANYL I EN HVILKEN SOM HELST AF DE FORMER, DER ER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/10/644/001-006 20100831
1635783	C300653	Netherlands		PRODUCT NAME: FENTANYL IN ELKE DOOR HET BASISOCTROOI BESCHERMDE VERSCHIJNINGSVORM; REGISTRATION NO/DATE: EU/1/10/644/001-004 20100906

Market Dynamics and Financial Trajectory for IONSYS (Fentanyl iontrophoretic transdermal system)

Last updated: July 29, 2025

Introduction

IONSYS (fentanyl iontrophoretic transdermal system) represents an innovative pain management delivery device introduced by Grifols, designed for acute post-operative pain control in hospitalized settings. As a legible entrant within the opioid analgesics market, IONSYS’s market performance hinges on evolving regulatory environments, clinical acceptance, competitive pressures, and socio-economic factors shaping opioid use and pain management standards globally. This comprehensive analysis explores the market dynamics influencing IONSYS’s commercial trajectory and projects its financial outlook over the coming years.

Market Overview and Positioning of IONSYS

IONSYS employs iontophoretic technology to deliver fentanyl transdermally, providing patients with controlled, immediate analgesia at the push of a button—an attribute that distinguishes it from traditional opioid delivery methods such as intravenous (IV) therapy or oral opioids. The device’s design emphasizes rapid onset, patient-controlled dosing, and minimal systemic side effects, aligning with modern pain management protocols favoring patient autonomy and safety.

Despite FDA approval in 2007 and subsequent regulatory clearances in multiple markets, IONSYS’s adoption has reflected a niche legacy, constrained primarily by concerns over opioid misuse, regulatory restrictions, and reimbursement challenges [1].

Regulatory and Ethical Influences

The global opioid landscape is complex. While opioids like fentanyl are indispensable in managing severe pain, regulatory scrutiny has intensified due to the opioid epidemic, particularly in North America. In the US, the FDA's 2019 decision to withdraw approval for IONSYS, citing safety issues, significantly curtailed its market presence. Conversely, in select European and Asia-Pacific markets, regulatory agencies have adopted a more measured approach, allowing continued or expanded use under specific guidelines [2].

This regulatory bifurcation impacts market dynamics by restricting commercialization in core markets like the US, while enabling growth opportunities elsewhere. Manufacturers must adapt R&D and marketing strategies accordingly, seeking pathways for regulatory reapproval or alternative indications.

Competitive Landscape and Market Share Dynamics

The pain management device sector faces intense competition from both traditional formulations—such as IV morphine and PCA (patient-controlled analgesia)—and emerging delivery systems, including non-opioid alternatives and advanced patient-controlled analgesia devices. The main competitors for IONSYS include:

• Continuous nerve block systems
• Non-opioid analgesic patches
• Digital health platforms integrating pain tracking

While IONSYS has a technological edge in rapid, patient-controlled fentanyl delivery, its market share remains limited due to safety concerns, costs, and clinician familiarity with established modalities. Moreover, the rise of multimodal pain regimens incorporating non-opioid agents diminishes reliance on opioid-based systems in some clinical settings [3].

Evolving Market Drivers

Several factors underpin future market growth for IONSYS:

• Post-operative pain management trends: There's a paradigm shift favoring patient-controlled, minimally invasive, and fast-acting analgesia, aligning with IONSYS's strengths.
• Healthcare system pressures: Institutions emphasizing reduced hospital stay durations and improved patient satisfaction may favor innovative delivery systems that enable early mobilization and better pain control.
• Global opioid regulations: In regions where regulatory restrictions are less stringent, and opioid stewardship is balanced with effective pain management, IONSYS could expand its market share.
• Technological advancements: Improvements in IONSYS’s device design, safety features, and integration with digital health platforms could enhance clinician acceptance and patient outcomes.

Financial Trajectory and Revenue Projections

Historical Financial Context:
Due to limited global deployment—primarily constrained by regulatory barriers—the revenue from IONSYS has historically been modest. In 2020, estimated sales hovered around $10-15 million globally, predominantly from European markets, with negligible contributions from the US.

Projected Growth Factors:

• Market Expansion: Targeted efforts to regain US regulatory approval could unlock significant revenue, considering the large post-operative analgesic market (~$6 billion in the US alone).
• Regulatory Re-approvals and Indications: Demonstrating improved safety profiles and obtaining approvals for broader indications could catalyze sales.
• Strategic Partnerships: Collaborations with hospital networks and pain management specialty groups could facilitate adoption.

Forecast Scenarios:

• Conservative Scenario: Limited US approval and slow growth in other markets may sustain annual revenues at $15-25 million over next five years, with incremental gains from existing European markets.
• Optimistic Scenario: Successful FDA reapproval, adoption of newer device iterations, and expanded indications could propel revenues to $100 million or more within five years.
• Downside Risks: Stringent regulations, safety concerns, and competition could hinder growth, leading to stagnation or decline.

Investment and R&D Outlook:
Continuous R&D aimed at safety enhancements, alternative delivery mechanisms, and digital integration could position IONSYS favorably for future growth, especially if regulatory pathways are navigated successfully.

Market Challenges and Opportunities

Challenges

• Safety and Abuse Potential: Opioid misuse concerns, especially with fentanyl’s high potency, remain a primary barrier.
• Regulatory Uncertainty: Shifts in policy and safety concerns may result in approval delays or restrictions.
• High Cost and Reimbursement: The device’s cost relative to traditional analgesic modalities may limit adoption, especially in cost-sensitive markets.

Opportunities

• Regenerative and Non-opioid Pain Therapeutics: Integration or replacement with alternative therapies could set new standards.
• Digital Health Integration: Incorporation of remote monitoring and data analytics could enhance safety profiles and justify premium pricing.
• Global Expansion: Markets with evolving opioid regulations and high surgical volumes present growth fronts.

Conclusion

IONSYS occupies a specialized niche within the analgesic delivery landscape, with a promising technological foundation but limited current market penetration. Its future financial trajectory depends heavily on regulatory environments, safety profile enhancements, and strategic market positioning. While regulatory setbacks like the US FDA withdrawal constrain immediate growth prospects, targeted efforts in other regions, coupled with ongoing R&D and strategic partnerships, could catalyze a robust rebound.

Proactive adaptation to evolving pain management paradigms and regulatory frameworks will be critical to unlocking IONSYS’s full market potential.

---

Key Takeaways

• Regulatory environment is pivotal: US FDA withdrawal restricts market access, but European and Asian approvals offer growth opportunities.
• Safety concerns limit adoption: Addressing opioid misuse and safety issues through device innovation is essential.
• Market remains niche but promising: Post-operative pain management remains an underserved segment with high unmet needs.
• Strategic partnerships and R&D are key: Collaborations and technological enhancements can accelerate market penetration.
• Financial upside hinges on regulatory success: Reaffirmation of safety and expanded indications would significantly improve revenue prospects.

---

FAQs

1. What are the primary barriers to IONSYS's broader market adoption?
Safety concerns regarding opioid misuse, regulatory restrictions—particularly in the US—and high device costs impede widespread adoption.

2. How might regulatory changes impact IONSYS's future sales?
Easing of restrictions or successful reapproval in key markets like the US could significantly accelerate sales, while stricter controls could further limit growth.

3. Are there competing technologies that threaten IONSYS's market share?
Yes. Non-opioid analgesic patches, advanced nerve block devices, and digital pain management platforms provide alternatives, reducing reliance on opioid-based systems.

4. What strategies can enhance IONSYS's market prospects?
Improving safety profiles, expanding indications, forming strategic collaborations, and innovating device features are critical strategies.

5. What is the outlook for IONSYS in Asian markets?
Growing surgical volumes, evolving regulatory frameworks, and increasing acceptance of innovative analgesics position Asia as a significant growth opportunity, contingent on regulatory clearance and safety acceptance.

---

Sources:
[1] U.S. Food and Drug Administration. (2019). FDA Drug Safety Communication.
[2] European Medicines Agency. (2021). Regulatory updates on opioid analgesics.
[3] MarketsandMarkets. (2020). Pain Management Devices Market by Type, Application, and Region.